The expression profile of platelet‐derived miRNA in coronary artery disease patients with clopidogrel resistance

Lin, Song; Xu, Xiaofeng; Hu, Haochang; Ji, Cheng; Chen, Ruoyu; Hu, Yingchu; Chen, Xiaomin

doi:10.1002/prp2.751

Cited by 5 publications

(6 citation statements)

References 39 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies to date aimed to identify an improved biomarker for cardiovascular risk stratification and assessment of platelet reactivity, among them miRNAs are currently becoming the centre of scientific attention [ 47 ]. Indeed, several correlations between miRNA concentrations and platelet reactivity have been found [ 36 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 ] ( Figure 2 ).…”

Section: Mirnas Expression and Platelet Reactivitymentioning

confidence: 99%

“…The first possibility is an miRNA high-throughput sequencing in a small group of patients (resistant to the therapy compared to controls). It allows one to obtain miRNA expression profiles and select specific miRNAs for further analysis by qPCR [ 54 ]. The other commonly applied option is to investigate only miRNAs with a known function, since they are more likely to present an altered expression in the studied group [ 56 , 61 ].…”

Section: Mirnas Expression and Platelet Reactivitymentioning

confidence: 99%

“…In contrast, miR-130 expression also showed a correlation with platelet reactivity similar to miR-126 and miR-223 but only in healthy volunteers [ 55 ]. Lin et al found that platelet miR-411-3p is downregulated, while miR-142-3p and miR-24-3p are upregulated in clopidogrel-resistant CAD patients [ 54 ]. Finally, Liu et al showed that PRI values correlated negatively with platelet miR-223-3p expression among CAD patients [ 56 ].…”

Section: Mirnas Expression and Platelet Reactivitymentioning

confidence: 99%

See 2 more Smart Citations

Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring

Procyk

Klimczak-Tomaniak

Sygitowicz

et al. 2022

JCM

View full text Add to dashboard Cite

Micro-ribonucleic acids (microRNAs) are small molecules that take part in the regulation of gene expression. Their function has been extensively investigated in cardiovascular diseases (CVD). Most recently, miRNA expression levels have been suggested as potential biomarkers of platelet reactivity or response to antiplatelet therapy and tools for risk stratification for recurrence of ischemic evens. Among these, miR-126 and miR-223 have been found to be of particular interest. Despite numerous studies aimed at understanding the prognostic value of miRNA levels, no final conclusions have been drawn thus far regarding their utility in clinical practice. The aim of this review is to critically appraise the evidence on the association between miRNA expression, cardiovascular risk and on-treatment platelet reactivity as well as provide insights on future developments in the field.

show abstract

Section: Mirnas Expression and Platelet Reactivitymentioning

confidence: 99%

Section: Mirnas Expression and Platelet Reactivitymentioning

confidence: 99%

Section: Mirnas Expression and Platelet Reactivitymentioning

confidence: 99%

See 1 more Smart Citation

Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring

Procyk

Klimczak-Tomaniak

Sygitowicz

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Lower expression of miR-126, miR-130, and miR-223 is also been observed in the ACS patients with high platelet reactivity (HPR) to clopidogrel than those with low platelet reactivity (LPR) ( 195 ). A more recent study also reported that increased expression of miR-24-3p, miR-142-3p, and miR-411-3p was positively correlated with clopidogrel resistance (CR) in CAD patients ( 205 ). Similarly, miR-29, miR-34, miR-126, miR-142, and miR-223 are also reported to be novel biomarkers for P2Y12 inhibitor resistance prediction ( 206 ).…”

Section: Introductionmentioning

confidence: 97%

Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target

Leng

Ding

Dai

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Non-communicable diseases (NCDs), represented by cardiovascular diseases and cancer, have been the leading cause of death globally. Improvements in mortality from cardiovascular (CV) diseases (decrease of 14%/100,000, United States) or cancers (increase 7.5%/100,000, United States) seem unsatisfactory during the past two decades, and so the search for innovative and accurate biomarkers of early diagnosis and prevention, and novel treatment strategies is a valuable clinical and economic endeavor. Both tumors and cardiovascular system are rich in angiological systems that maintain material exchange, signal transduction and distant regulation. This pattern determines that they are strongly influenced by circulating substances, such as glycolipid metabolism, inflammatory homeostasis and cyclic non-coding RNA and so forth. Platelets, a group of small anucleated cells, inherit many mature proteins, mRNAs, and non-coding RNAs from their parent megakaryocytes during gradual formation and manifest important roles in inflammation, angiogenesis, atherosclerosis, stroke, myocardial infarction, diabetes, cancer, and many other diseases apart from its classical function in hemostasis. MicroRNAs (miRNAs) are a class of non-coding RNAs containing ∼22 nucleotides that participate in many key cellular processes by pairing with mRNAs at partially complementary binding sites for post-transcriptional regulation of gene expression. Platelets contain fully functional miRNA processors in their microvesicles and are able to transport their miRNAs to neighboring cells and regulate their gene expression. Therefore, the importance of platelet-derived miRNAs for the human health is of increasing interest. Here, we will elaborate systematically the roles of platelet-derived miRNAs in cardiovascular disease and cancer in the hope of providing clinicians with new ideas for early diagnosis and therapeutic strategies.

show abstract

“…MiRNAs are short-length noncoding RNAs that could directly interact with the 3′-untranslated regions (UTR) of target mRNAs, hence modulate gene transcription and cause RNA degradation [ 14 , 15 ]. Owing to the large scale of targeted genes, miRNAs are found to participate in various cellular processes, including cell proliferation, migration, and apoptosis [ 16 ]. For example, inhibition of miR-495 alleviated intimal hyperplasia and notably decreased formation of atherosclerotic plaque, modulated macrophage influx, cholesterol level in plasma, and plaque stability [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

The expression profile of platelet‐derived miRNA in coronary artery disease patients with clopidogrel resistance

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cited by 5 publications

References 39 publications

Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring

Circulating and Platelet MicroRNAs in Cardiovascular Risk Assessment and Antiplatelet Therapy Monitoring

Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target

MiR-7-5p attenuates vascular smooth muscle cell migration and intimal hyperplasia after vascular injury by NF-kB signaling

Contact Info

Product

Resources

About